Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade

To the Editor: Patients with autoimmune diseases have typically been excluded from immunotherapy clinical trials, although recent evidence suggests that the benefits of checkpoint therapy may outweigh the risks of autoimmune flare-ups in carefully selected patients who have a high probability of…

http://ift.tt/2pZRYIE